Tau-Centric Multitarget Approach for Alzheimer’s Disease: Development of First-in-Class Dual Glycogen Synthase Kinase 3β and Tau-Aggregation Inhibitors
Annachiara Gandini(Scuola Internazionale Superiore di Studi Avanzati), María Laura Bolognesi(University of Bologna), Josefa Zaldívar-Díez(Centro de Investigaciones Biológicas Margarita Salas), Andrea Miti(National Research Council), Loreto Martínez‐González(Consejo Superior de Investigaciones Científicas), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Daniele Tedesco(University of Bologna), Giampaolo Zuccheri(National Research Council), Sabrina Castellano(University of Salerno), Alessandra Feoli(University of Salerno), Fabio Moda(University of Milan), Manuela Bartolini(University of Bologna), Sabrina Petralla(Heidelberg University), Barbara Monti(University of Bologna), Carlos Roca(Centro de Investigaciones Biológicas Margarita Salas), Giuseppe Legname(International Center for Advanced Studies), Concepción Pérez(Instituto de Química Médica), Nuria E. Campillo(Centro de Investigaciones Biológicas Margarita Salas)
Cited by 104
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293